We previously reported that PegC, in combination with the Bcl2 inhibitor venetoclax, inhibits protein synthesis through interference with cap-dependent mRNA translation downstream of mTOR signaling in acute myeloid leukemia (AML) [17, 20]. Here, BCL2 is linked to acute myeloid leukemia.